Shannon Ronald, Nelson Andrea
Global Health Economic Projects LLC, Clifton Park, NY, USA.
Head of School, School of Healthcare, University of Leeds, Leeds, UK.
Int Wound J. 2017 Aug;14(4):729-741. doi: 10.1111/iwj.12687. Epub 2016 Nov 20.
To compare data on time to healing from two separate cohorts: one treated with a new acellular synthetic matrix plus standard care (SC) and one matched from four large UK pragmatic, randomised controlled trials [venous leg ulcer (VLU) evidence network]. We introduce a new proof-of-concept strategy to a VLU clinical evidence network, propensity score matching and sensitivity analysis to predict the feasibility of the new acellular synthetic matrix plus SC for success in future randomised, controlled clinical trials. Prospective data on chronic VLUs from a safety and effectiveness study on an acellular synthetic matrix conducted in one wound centre in the UK (17 patients) and three wound centres in Australia (36 patients) were compared retrospectively to propensity score-matched data from patients with comparable leg ulcer disease aetiology, age, baseline ulcer area, ulcer duration, multi-layer compression bandaging and majority of care completed in specialist wound centres (average of 1 visit per week), with the outcome measures at comparable follow-up periods from patients enrolled in four prospective, multicentre, pragmatic, randomised studies of venous ulcers in the UK (the comparison group; VLU evidence network). Analysis using Kaplan-Meier survival curves showed a mean healing time of 73·1 days for ASM plus SC (ASM) treated ulcers in comparison with 83·5 days for comparison group ulcers treated with SC alone (Log rank test, χ 5·779, P = 0·016) within 12 weeks. Sensitivity analysis indicates that an unobserved covariate would have to change the odds of healing for SC by a factor of 1·1 to impact the baseline results. Results from this study predict a significant effect on healing time when using a new ASM as an adjunct to SC in the treatment of non-healing venous ulcers in the UK, but results are sensitive to unobserved covariates that may be important in healing time comparison.
一个队列接受新型脱细胞合成基质加标准护理(SC)治疗,另一个队列从英国四项大型实用随机对照试验[静脉性腿部溃疡(VLU)证据网络]中匹配而来。我们将一种新的概念验证策略引入VLU临床证据网络,即倾向评分匹配和敏感性分析,以预测新型脱细胞合成基质加SC在未来随机对照临床试验中取得成功的可行性。对英国一个伤口中心(17例患者)和澳大利亚三个伤口中心(36例患者)进行的关于脱细胞合成基质的安全性和有效性研究中的慢性VLU前瞻性数据,与来自具有可比腿部溃疡疾病病因、年龄、基线溃疡面积、溃疡持续时间、多层加压包扎且大部分护理在专科伤口中心完成(平均每周1次就诊)的患者的倾向评分匹配数据进行回顾性比较,结局指标来自英国四项关于静脉溃疡的前瞻性、多中心、实用、随机研究(对照组;VLU证据网络)的患者在可比随访期的情况。使用Kaplan-Meier生存曲线分析显示,在12周内,接受ASM加SC(ASM)治疗的溃疡平均愈合时间为73.1天,而仅接受SC治疗的对照组溃疡平均愈合时间为83.5天(对数秩检验,χ² = 5.779,P = 0.016)。敏感性分析表明,一个未观察到的协变量必须将SC愈合的几率改变1.1倍才能影响基线结果。本研究结果预测,在英国治疗不愈合的静脉溃疡时,使用新型ASM作为SC的辅助治疗对愈合时间有显著影响,但结果对可能在愈合时间比较中很重要的未观察到的协变量敏感。